Estrone (E1)

Hormones

Sex Hormone Metabolism

Estrone (E1) is a weaker estrogen that becomes the predominant form after menopause, when it is produced largely from fat tissue rather than the ovaries. Because adipose tissue drives its production through aromatase, estrone levels are closely tied to body composition. A preventive practice tracks it to understand estrogen status, particularly in the menopausal transition.

What It Measures

Weaker estrogen; primary estrogen in menopause (produced from fat tissue)

Optimal vs. Lab Range

Longevity Optimal

Menopausal: context-dependent

Target range for optimal health and longevity based on research.

Standard Lab

17–200 pg/mL (premenopausal)

Population-based reference range from standard labs.

Why It Matters

Estrone's link to fat tissue makes it a marker where metabolic and hormonal health intersect. High levels are associated with obesity through increased aromatase activity, as well as liver disease and estrogen-sensitive conditions, while low levels can reflect ovarian insufficiency, menopause, or very low body fat. Because estrone becomes the main estrogen after menopause, its interpretation is highly context-dependent and shaped by life stage and body composition. Considered alongside estradiol, estriol, SHBG, and body composition, estrone helps round out the estrogen picture and informs conversations about weight, metabolic health, and long-term hormonal balance.

When Low

Ovarian insufficiency, menopause, low body fat

When High

Obesity (increased aromatase), estrogen-dependent cancers, liver disease

How to Optimize

Because estrone tracks closely with adipose tissue, weight management is often the most influential lever, reducing the aromatase-driven conversion that raises it. In specific situations, clinicians may consider estrogen-metabolism support such as DIM or broader aromatase management. Interpretation and any intervention depend heavily on menopausal status and the full estrogen panel. Hormone testing and treatment must be individualized with your physician; this content is educational and not a substitute for medical advice.

Key Interventions & Linked Compounds

Moderate evidence

Key Interventions

Weight management

aromatase management

DIM

Linked Compounds & Supplements

DIM

Calcium-D-Glucarate

Curated from clinical literature. Individual results vary; consult a qualified clinician before changing a protocol.

Ordering Notes

Specimen

Serum; saliva for diurnal cortisol panels

Patient prep

No fasting required. Maintain usual diet and medications unless advised.

Recommended cadence

Semi-annual

Reporting unit

Confirm with the performing lab — units vary by region.

Pre-analytic notes

Standardize draw time of day, hydration, and recent exercise. Note any acute illness, supplements, or hormonal therapies on the requisition.

Recommended Follow-Up Actions

1
Confirm the result is reliable
Repeat abnormal values before acting — preferably from the same lab, same time of day, and under consistent prep. Rule out acute illness, recent intense exercise, or medication effects that can shift Estrone (E1).
2
Compare against optimal, not just lab range
Use the optimal window above as the target. Lab "normal" is built from the general population and often misses early dysfunction.
3
Pair with related markers
Order a complementary panel covering metabolic, inflammatory, and hormonal context to interpret this marker properly.
4
Discuss interventions with a clinician
Use the interpretation guidance above to frame the conversation. Bring trends, not just one datapoint, to your visit.
5
Re-test on a defined cadence
If a change is implemented, re-measure in 8–12 weeks for fast-moving markers, or 3–6 months for slower ones, to confirm response before escalating.